UBEUBE Corporation4208東証プライム化学FY ending Mar 2026, consolidated, J-GAAP

Which UBE businesses make the profit?

Revenue by business segment, and the profit each one keeps.

Revenue by geography

Geographic revenue reported in annual filings

No geographic revenue breakdown was disclosed.

※ Segment figures include inter-segment sales and do not sum to the company total

Revenue and profit mix

FY ending Mar 2026

Revenue mix

Profit mix (profitable segments)

Specialty Products accounts for 12% of revenue and 40% of profit.

  • Specialty Products
    Revenue 12.3%Profit 40.3%Difference +28.0 ptMargin 19.2%Chemicals
  • Machinery
    Revenue 16.4%Profit 25.8%Difference +9.4 ptMargin 9.2%Industrial Machinery
  • Polymers and Chemicals
    Revenue 55.1%Profit 33.9%Difference -21.3 ptMargin 3.6%Chemicals
  • High Performance Urethans
    Revenue 11.1%Margin -1.2%Chemicals
  • Pharmaceutical
    Revenue 5.0%Margin -6.1%Pharmaceuticals

Loss-making segments (excluded from profit bar)

High Performance Urethans: -¥548M

Pharmaceutical: -¥1.25B

Calculated from disclosed figures; listed by margin. Difference = profit share − revenue share (percentage points). Segment revenues may include inter-segment sales and may not sum to company revenue.

Business growth × margin

X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.

Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.

Segment history (JPY millions)

SegmentRevenue CAGRFY ending Mar 2022FY ending Mar 2023FY ending Mar 2024FY ending Mar 2025FY ending Mar 2026
Chemicals—340,67510.4%————
Specialty Products+1.7%4y47,69424.4%47,08521.8%46,14226.2%50,25023.2%50,93019.2%
Cement and construction materials—217,3531.6%————
Polymers and Chemicals-0.6%4y233,92110.1%268,4691.0%244,6201.0%255,248-0.3%228,4193.6%
Machinery-2.5%5y95,5795.4%96,3735.4%96,4767.4%86,3629.1%68,0879.2%
High Performance UrethansN/A———15,067-1.3%46,130-1.2%
PharmaceuticalN/A———29,7803.9%20,640-6.1%

Top: revenue. Bottom: operating margin.

Sources

Show source documents (6)
  • EDINET (FSA Japan)

    有価証券報告書-第120期(2025/04/01-2026/03/31)

    ID S100YD422026-06-18Open
  • EDINET (FSA Japan)

    有価証券報告書-第119期(2024/04/01-2025/03/31)

    ID S100W0482025-06-20Open
  • EDINET (FSA Japan)

    有価証券報告書-第118期(2023/04/01-2024/03/31)

    ID S100TOHR2024-06-21Open
  • EDINET (FSA Japan)

    訂正有価証券報告書-第117期(2022/04/01-2023/03/31)

    ID S100RTQV2023-09-08Open
  • EDINET (FSA Japan)

    有価証券報告書-第116期(令和3年4月1日-令和4年3月31日)

    ID S100OIQR2022-06-29Open
  • EDINET (FSA Japan)

    有価証券報告書-第115期(令和2年4月1日-令和3年3月31日)

    ID S100LSYZ2021-06-29Open

Extracted from XBRL: 56 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.